383 related articles for article (PubMed ID: 18296421)
1. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Untch M; Gelber RD; Jackisch C; Procter M; Baselga J; Bell R; Cameron D; Bari M; Smith I; Leyland-Jones B; de Azambuja E; Wermuth P; Khasanov R; Feng-Yi F; Constantin C; Mayordomo JI; Su CH; Yu SY; Lluch A; Senkus-Konefka E; Price C; Haslbauer F; Suarez Sahui T; Srimuninnimit V; Colleoni M; Coates AS; Piccart-Gebhart MJ; Goldhirsch A;
Ann Oncol; 2008 Jun; 19(6):1090-6. PubMed ID: 18296421
[TBL] [Abstract][Full Text] [Related]
2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
3. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
4. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
5. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sánchez Rovira P; Piccart-Gebhart MJ;
Lancet; 2007 Jan; 369(9555):29-36. PubMed ID: 17208639
[TBL] [Abstract][Full Text] [Related]
6. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
8. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Goldhirsch A; Gelber RD; Piccart-Gebhart MJ; de Azambuja E; Procter M; Suter TM; Jackisch C; Cameron D; Weber HA; Heinzmann D; Dal Lago L; McFadden E; Dowsett M; Untch M; Gianni L; Bell R; Köhne CH; Vindevoghel A; Andersson M; Brunt AM; Otero-Reyes D; Song S; Smith I; Leyland-Jones B; Baselga J;
Lancet; 2013 Sep; 382(9897):1021-8. PubMed ID: 23871490
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
Kim MM; Dawood S; Allen P; Sahin AA; Woodward WA; Smith BD; Strom EA; Hunt KK; Meric-Bernstam F; Gonzalez-Angulo AM; Buchholz TA
Cancer; 2012 Oct; 118(20):4936-43. PubMed ID: 22511276
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
Partridge AH; Gelber S; Piccart-Gebhart MJ; Focant F; Scullion M; Holmes E; Winer EP; Gelber RD
J Clin Oncol; 2013 Jul; 31(21):2692-8. PubMed ID: 23752109
[TBL] [Abstract][Full Text] [Related]
12. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
Zabaglo L; Stoss O; Rüschoff J; Zielinski D; Salter J; Arfi M; Bradbury I; Dafni U; Piccart-Gebhart M; Procter M; Dowsett M;
Ann Oncol; 2013 Nov; 24(11):2761-6. PubMed ID: 23894039
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
O'Sullivan CC; Bradbury I; Campbell C; Spielmann M; Perez EA; Joensuu H; Costantino JP; Delaloge S; Rastogi P; Zardavas D; Ballman KV; Holmes E; de Azambuja E; Piccart-Gebhart M; Zujewski JA; Gelber RD
J Clin Oncol; 2015 Aug; 33(24):2600-8. PubMed ID: 26101239
[TBL] [Abstract][Full Text] [Related]
14. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
[TBL] [Abstract][Full Text] [Related]
15. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
17. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Pestalozzi BC; Holmes E; de Azambuja E; Metzger-Filho O; Hogge L; Scullion M; Láng I; Wardley A; Lichinitser M; Sanchez RI; Müller V; Dodwell D; Gelber RD; Piccart-Gebhart MJ; Cameron D
Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
[TBL] [Abstract][Full Text] [Related]
18. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
